The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy
Open accessAbstract
Thirty-one patients treated with mesenchymal stromal cells (MSCs) for acute graft-versus-host disease (aGVHD) or hemorrhagic cystitis between 2002 and 2007 were followed to investigate predictors of outcome, immunologic effects in vivo, and long-term survival. There was no correlation between in vitro suppression by MSCs in mixed lymphocyte cultures and outcome. Soluble IL-2 receptors were measured in blood before and after MSC infusion and declined significantly during the first week after MSC infusion (P = .03). Levels of interleukin-6 and HLA-G were unaffected. Infectious complications occurred several years after recovery from aGVHD. Cytomegalovirus viral load was high, and cytomegalovirus disease was common. Among patients recovering from aGVHD, 54% died of late infections, between 4 months and 2 years after MSC treatment. No increase in leukemia relapse or graft rejection was found. Children had a better survival rate than adults (P = .005). In GVHD patients, 1-year survival was 75% in patients who received early-passage MSCs (from passages 1-2) in contrast to 21% using later passage MSCs (from passages 3-4) (P < .01). We conclude that treatment with early-passage MSCs improved survival in patients with therapy-resistant GVHD. Death from infection was common in MSC-treated patients, but there was no increase in leukemia relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Self-citationHeterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.
Friedenstein, A. J., Kv, P., KUROLESOVA, A. I., & Frolova, G. P. (1968) · PubMed · Cited by 1,921
HETEROTOPIC TRANSPLANTS OF BONE MARROW
FRIEDENSTEIN, A. J., PETRAKOVA, K. V., KUROLESOVA, A. I., & FROLOVA, G. P. (1968) · Transplantation · doi:10.1097/00007890-196803000-00009 · Cited by 1,699
Le Blanc, K., Tammik, L., Sundberg, B., Haynesworth, S. E., & Ringdén, O. (2003) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2003.01176.x · Cited by 1,368
Self-citationCharacterization of cells with osteogenic potential from human marrow
Haynesworth, S. E., Goshima, J., Goldberg, V. M., & Caplan, A. I. (1992) · Bone · doi:10.1016/8756-3282(92)90364-3 · Cited by 1,289
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
Ljungman, P., Griffiths, P., & Paya, C. (2002) · Clinical Infectious Diseases · doi:10.1086/339329 · Cited by 1,234
Self-citationMesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., Marschall, H.-U., Dlugosz, A., Szakos, A., Hassan, Z., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000214462.63943.14 · Cited by 1,142
Self-citationThe Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion
Gao, J., Dennis, J. E., Muzic, R. F., Lundberg, M., & Caplan, A. I. (2001) · Cells Tissues Organs · doi:10.1159/000047856 · Cited by 951
Emery, V. C., Sabin, C. A., Cope, A. V., Gor, D., Hassan-Walker, A. F., & Griffiths, P. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02350-3 · Cited by 545
Le Blanc, K., & Ringdén, O. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.01.005 · Cited by 471
Self-citationChapel, A., Bertho, J. M., Bensidhoum, M., Fouillard, L., Young, R. G., Frick, J., Demarquay, C., Cuvelier, F., Mathieu, E., Trompier, F., et al. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.452 · Cited by 460
Ning, H., Yang, F., Jiang, M., Hu, L., Feng, K., Zhang, J., Yu, Z., Li, B., Xu, C., Li, Y., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405090 · Cited by 407
Immunosuppressive Effects of Mesenchymal Stem Cells: Involvement of HLA-G
Nasef, A., Mathieu, N., Chapel, A., Frick, J., François, S., Mazurier, C., Boutarfa, A., Bouchet, S., Gorin, N.-C., Thierry, D., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000267918.07906.08 · Cited by 350
Implication of HLA-G molecule in heart-graft acceptance
Lila, N., Carpentier, A., Amrein, C., Khalil-Daher, I., Dausset, J., & Carosella, E. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02386-2 · Cited by 224
Ringdén, O., Uzunel, M., Sundberg, B., Lönnies, L., Nava, S., Gustafsson, J., Henningsohn, L., & Le Blanc, K. (2007) · Leukemia · doi:10.1038/sj.leu.2404833 · Cited by 208
Self-citationMesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
Karlsson, H., Samarasinghe, S., Ball, L. M., Sundberg, B., Lankester, A. C., Dazzi, F., Uzunel, M., Rao, K., Veys, P., Le Blanc, K., et al. (2008) · Blood · doi:10.1182/blood-2007-10-119370 · Cited by 164
Self-citationMattsson, J., Uzunel, M., Remberger, M., & Ringdén, O. T. H. (2001) · Transplantation · doi:10.1097/00007890-200102150-00017 · Cited by 102
Self-citationOptimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
Samuelsson, H., Ringdén, O. T. H., Lönnies, H., & Blanc, K. L. (2009) · Cytotherapy · doi:10.1080/14653240802684194 · Cited by 75
Self-citationAdvances in the clinical management of GVHD
Ferrara, J. L. M. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.07.003 · Cited by 34
Cited by
Mesenchymal stem cells: immune evasive, not immune privileged
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2816 · Cited by 1,531
Challenges and Controversies in Human Mesenchymal Stem Cell Therapy
Lukomska, B., Stanaszek, L., Zuba-Surma, E., Legosz, P., Sarzynska, S., & Drela, K. (2019) · Stem Cells International · doi:10.1155/2019/9628536 · Cited by 550
Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy
Phinney, D. G. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24166 · Cited by 434
Moll, G., Alm, J. J., Davies, L. C., von Bahr, L., Heldring, N., Stenbeck-Funke, L., Hamad, O. A., Hinsch, R., Ignatowicz, L., Locke, M., et al. (2014) · Stem Cells · doi:10.1002/stem.1729 · Cited by 381
Self-citation
Metadata
- Authors
- von Bahr, L., Sundberg, B., Lönnies, L., Sander, B., Karbach, H., Hägglund, H., Ljungman, P., Gustafsson, B., Karlsson, H., Le Blanc, K., & Ringdén, O.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 18
- Issue
- 4
- Pages
- 557-564
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2102330961
- Cited by
- 318
- References
- 20
- FWCI
- 13.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.